Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
450.32 K
Value Traded
482.03 K
Short % Float
2.25%
Days to Cover
1.5
-6.25%Week
-49.76%1 Month
-65%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
19.61 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
18.63 M
Total Shares
18.67 M
Float Shares
12.73 M
Insiders
31.80%
Institutions
11.42%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BSEM Catalyst Timeline
Dated clinical, regulatory and corporate events for BioStem Technologies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioStem Technologies, Inc.
27Total events
8Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 15
▲Patent GrantedIP / Competition
USPTO issues U.S. Patent No. 12,648,969 for sterile human placental allografts
wounds and diabetic foot ulcerssource ↗
▼Equity OfferingCorporate
Closed private placement with institutional investors for ~$3 million gross proceeds
▲Patent GrantedIP / Competition
USPTO notice of allowance for U.S. Patent Application No. 19/660,625 (sterile human placental allografts)
woundssource ↗
▼Equity OfferingCorporate
BioStem enters $40 million Committed Equity Facility with Roth Principal Investments
▲Patent GrantedIP / Competition
USPTO notice of allowance for U.S. Patent Application No. 19/681,608 (micronized umbilical cord and amnion-chorion compositions)
wound healingsource ↗
▲Patent GrantedIP / Competition
USPTO notice of allowance for U.S. Patent Application No. 17/873,383 (umbilical cord extract for joint cushioning and lubrication)
joint inflammationsource ↗
Past FDA Catalysts and PDUFA Decisions
How BSEM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BSEM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| POE BRANDONOfficer (Chief Financial Officer) | Option | 2,699 60,763 held | $0.00 | 11/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BSEM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BSEM for Q2 2026. | ||||
Ownership Trends
BSEM Short Interest
Shares sold short, counted twice a month.
2.25%
Short % of Float
of tradable shares sold short
286.9K
Shares Sold Short
-14.0% vs prior count
1.5 Low
Days to Cover
trading days of normal volume to buy every short share back
187.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BSEM ranks across every disease it competes in
Competitive Position is a premium feature
See how BSEM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBSEM News
-BSEM
Nov 12, 2026▼ -19.2%on this news
BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio
BioStem Technologies reported a third quarter revenue of $7.6 million, with hospital revenue increasing to $6.8 million. The company saw a 14% rise in customers buying multiple product lines and raised its full-year revenue guidance. However, it also reported a GAAP net loss of $11.4 million, up from the previous quarter.
Read more →-BSEM
Oct 29, 2026▼ -13.2%on this news
BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026
BioStem Technologies, Inc. will announce its third quarter 2026 financial results on November 12, 2026. A conference call and webcast will follow at 4:30 PM ET, featuring insights from management. The company focuses on regenerative medicine and has a portfolio of advanced allograft solutions.
Read more →-BSEM
Oct 8, 2026▲ +10.5%on this news
BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
BioStem Technologies announced that its CEO and COO have exercised stock options, investing $1 million in the company. This move is seen as a vote of confidence in BioStem's growth potential and its extensive portfolio of perinatal tissue allografts. The additional capital is expected to enhance sales coverage and inventory for new hospital accounts.
Read more →-BSEM
Oct 1, 2026BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio
BioStem Technologies has announced the issuance of a new patent and three notices of allowance for its placental and umbilical cord tissue technologies. These developments enhance the company's intellectual property portfolio, which now includes over 100 patents globally. The innovations aim to improve wound care and joint treatment applications, reflecting BioStem's commitment to advancing regenerative medicine.
Read more →-BSEM
Sep 30, 2026▼ -19.3%on this newsshared move
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BioStem Technologies has announced a private placement to raise $3 million by issuing shares and warrants. The offering, priced at $4.08 per share, includes Series A and B warrants, with potential additional proceeds of $5.6 million if fully exercised. The funds will be used for working capital and general corporate purposes, pending customary closing conditions.
Read more →-BSEM
Sep 18, 2026▲ +8.7%on this news
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
BioStem Technologies has announced a $40 million Committed Equity Facility with Roth Principal Investments. This facility allows BioStem to issue shares at its discretion, providing flexible access to capital for working and corporate purposes. The company plans to file a registration statement with the SEC for the resale of shares, although there are risks related to market conditions and shareholder dilution.
Read more →-BSEM
Sep 4, 2026BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
BioStem Technologies has announced that its products VENDAJE and VENDAJE AC are now available through contracts with Vizient and Premier, enhancing access for hospitals. This marks a significant step in expanding the reach of BioStem's wound care solutions. The CEO emphasized the importance of these agreements in supporting the company's commercial strategy and patient care.
Read more →-BSEM
Sep 3, 2026BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BioStem Technologies Inc. (BSEM) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company's fireside chat will be accessible on September 11, 2026. BioStem focuses on developing and commercializing perinatal tissue allograft products, leveraging advanced processing technologies to enhance tissue preservation.
Read more →-BSEM
Aug 14, 2026▼ -6.5%on this news
BioStem Technologies to Present at the Sidoti MicroCap Conference
BioStem Technologies Inc. will present at the Sidoti MicroCap Virtual Conference on August 19, 2026. The presentation will be accessible live and in archive on the company's investor relations website. BioStem specializes in regenerative medicine, focusing on perinatal tissue allograft products and has a strong commitment to quality and innovation.
Read more →-BSEM
Aug 12, 2026▼ -18.4%on this newsshared move
BioStem Technologies Reports Second Quarter 2026 Financial Results
BioStem Technologies reported a 29% sequential revenue growth for Q2 2026, reaching $7.9 million. The company uplisted to the Nasdaq Capital Market and raised its full-year revenue guidance. Despite the positive revenue growth, BioStem recorded a net loss of $9.0 million, highlighting ongoing operational challenges.
Read more →-BSEM
Aug 6, 2026BioStem Technologies Announces Nasdaq Uplisting
BioStem Technologies Inc. has announced its uplisting to The Nasdaq Capital Market, with trading set to begin on August 7, 2026. This move is viewed as a milestone for the company, aimed at improving capital access and market visibility. CEO Jason Matuszewski highlighted the uplisting's potential to attract talent and support growth. Shareholders will not need to take any action regarding the listing.
Read more →-BSEM
Jul 29, 2026BioStem Technologies to Host Second Quarter 2026 Financial Results Conference Call on August 12, 2026
BioStem Technologies Inc. will release its second quarter 2026 financial results on August 12, 2026. The company will host a conference call and webcast at 4:30 PM ET to discuss the quarter's performance. BioStem is recognized for its advancements in regenerative medicine, particularly in perinatal tissue allograft products.
Read more →-BSEM
Jul 10, 2026▲ +14.7%on this news
BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission
BioStem Technologies Inc. filed a Form 10 registration statement with the SEC to register its common stock. This move is part of its strategy to uplist to the Nasdaq, which the CEO believes will enhance the company's credibility and access to capital. The registration process is a crucial step toward achieving this goal.
Read more →-BSEM
Jun 10, 2026BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
BioStem Technologies Inc. announced its participation in the Planet MicroCap Las Vegas 2026 Conference. The presentation is scheduled for June 17, 2026, at 3:00 PM ET. BioStem specializes in regenerative medicine, particularly perinatal tissue allograft products, and has received accreditation from the American Association of Tissue Banks.
Read more →-BSEM
Jun 9, 2026BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
BioStem Technologies appointed Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors on June 5, 2026. Glickman will chair the Compensation Committee, while both Sonenreich and Hannaway will join the Audit and Corporate Governance Committees. The changes follow the resignation of Thomas Dugan and Patrick Daly, leaving the board with seven members.
Read more →-BSEM
May 22, 2026BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
BioStem Technologies announced a $2.5 million private placement financing with its first institutional investor. The company will sell 746,269 shares at $3.35 each, aiming to enhance its capital position and support growth plans. The offering is expected to close around May 22, 2026, pending customary conditions.
Read more →-BSEM
May 14, 2026▼ -14.2%on this news
BioStem Technologies Reports First Quarter 2026 Financial Results
BioStem Technologies reported a net revenue of $6.1 million for Q1 2026, down from $10.1 million in Q4 2025. The company expanded its sales force and retired $3 million in debt. However, it faced a net loss of $8.8 million and a decrease in gross margin. BioStem is progressing towards a Nasdaq uplisting.
Read more →-BSEM
May 12, 2026BioStem Technologies to Present at the 16th Annual LD Micro Invitational
BioStem Technologies Inc. will present at the 16th Annual LD Micro Invitational on May 18, 2026. The presentation will be accessible via live and archived webcasts. The company specializes in regenerative medicine, focusing on perinatal tissue allograft products and has a strong commitment to quality and innovation.
Read more →-BSEM
Apr 30, 2026BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026
BioStem Technologies, Inc. will announce its first quarter 2026 financial results on May 14, 2026. A conference call and webcast will follow at 4:30 PM ET, featuring management's overview of the quarter. The company specializes in perinatal tissue allograft products and is committed to advancing regenerative medicine.
Read more →-BSEM
Apr 30, 2026BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
BioStem Technologies appointed Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Gorrell brings extensive experience in health law and compliance, which will support BioStem's growth and governance. CEO Jason Matuszewski emphasized her role in reinforcing the company's integrity as it aims for a Nasdaq uplisting.
Read more →About BioStem Technologies, Inc.
Headquarters2836 CENTER PORT CIRCLE, POMPANO BEACH, FL, 33604
BIOPHARMAWATCH ELITE
Trade the next BSEM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime